Skip to content
2000
Volume 22, Issue 5
  • ISSN: 1573-3998
  • E-ISSN: 1875-6417
file format pdf download PDF
file format text download EPUB
side by side viewer icon HTML

Abstract

Introduction

Clinical trials indicate that IDegLira is effective in treating type 2 diabetes mellitus (T2DM). This study aims to assess the efficacy and safety of IDegLira in T2DM comprehensively.

Methods

To identify relevant randomized controlled trials, we searched PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov. Risk Ratios (RR) and 95% Confidence Intervals (CI) were calculated using the Mantel-Haenszel approach for dichotomous outcomes. Mean Difference (MD) and 95% CI calculated by the inverse variance approach were applied to continuous outcomes.

Results

Twelve randomized controlled trials involving 7628 participants were included in this study. Compared with control groups, IDegLira has a significant hypoglycemic effect in reducing hemoglobin A1c (MD = −0.66; 95% CI [−0.85, −0.47]; < 0.00001), fasting plasma glucose (MD = −0.90; 95% CI [−1.40, −0.41]; = 0.0003), self-measured plasma glucose (MD = −0.82; 95% CI [−1.22, −0.42]; < 0.0001) and achieving the hemoglobin A1c level of < 7.0% (RR = 1.66; 95% CI [1.44, 1.92]; < 0.00001) or < 6.5% (RR = 2.13; 95% CI [1.76, 2.57]; < 0.00001). IDegLira outperforms insulin in achieving the target of HbA1c < 7.0 or < 6.5% without hypoglycemia and weight gain. Besides, IDegLira did not increase the incidence of adverse events and serious adverse events.

Discussion

In this section, IDegLira’s benefits on simultaneously achieving glycemic control, weight loss, and reduced hypoglycemia risk were summarized. The statistical results were carefully interpreted in conjunction with clinical concerns regarding T2DM complications, adverse effects, and cost-effectiveness differences. An expanded discussion was conducted on integrating individualized HbA1c goals as a dual endpoint, without increasing body weight or the risk of hypoglycemia. Finally, the limitations of the present study were indicated.

Conclusion

IDegLira exhibits a favorable glycemic control effect and acceptable adverse effects in T2DM. Superior performance in the target glycemic control, particularly suitable for T2DM patients who do not reach the target hemoglobin A1c and have comorbid CVD or obesity.

© 2026 The Author(s). Published by Bentham Science Publishers.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/cdr/10.2174/0115733998359708250822102217
2025-09-11
2026-04-17

  • From This Site

    /content/journals/cdr/10.2174/0115733998359708250822102217
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cdr/22/5/CDR-22-5-01.html?itemId=/content/journals/cdr/10.2174/0115733998359708250822102217&mimeType=html&fmt=ahah

References

  1. IDF diabetes atlas.Available from:https://www.diabetesatlas.org 2021
  2. Diagnosis and classification of diabetes mellitus.Diabetes Care201437S81S9010.2337/dc14‑S08124357215
     [Google Scholar]
  3. DeFronzoR.A. FerranniniE. GroopL. HenryR.R. HermanW.H. HolstJ.J. HuF.B. KahnC.R. RazI. ShulmanG.I. SimonsonD.C. TestaM.A. WeissR. Type 2 diabetes mellitus.Nat Rev Dis Primers2015111501910.1038/nrdp.2015.1927189025
     [Google Scholar]
  4. LaiteerapongN. HamS.A. GaoY. MoffetH.H. LiuJ.Y. HuangE.S. KarterA.J. Diabetes Care201942341642610.2337/dc17‑114430104301
     [Google Scholar]
  5. ChadhaM. JainS.M. ChawlaR. DharmalingamM. ChaudhuryT. TalwalkarP.G. TripathiS. SinghS.K. GutchM. DasguptaA. Evolution of guideline recommendations on insulin therapy in type 2 diabetes mellitus over the last two ecades: A narrative review.Curr Diabetes Rev2023198e16012321277710.2174/157339981966623011615020536650625
     [Google Scholar]
  6. GriffinT.P. DinneenS.F. In T2DM, weekly insulin icodec did not differ from daily glargine for reducing HbA 1c or significant/severe hypoglycemia.Ann Intern Med20211743JC3410.7326/ACPJ202103160‑03433646841
     [Google Scholar]
  7. ForstT. ChoudharyP. SchneiderD. LinetzkyB. PozzilliP. A practical approach to the clinical challenges in initiation of basal insulin therapy in people with type 2 diabetes.Diabetes Metab Res Rev2021376e341810.1002/dmrr.341833098260
     [Google Scholar]
  8. ZhaoX. WangM. WenZ. LuZ. CuiL. FuC. XueH. LiuY. ZhangY. GLP-1 receptor agonists: Beyond their pancreatic effects.Front Endocrinol (Lausanne)20211272113510.3389/fendo.2021.72113534497589
     [Google Scholar]
  9. MoreiraR.O. CobasR. Lopes Assis CoelhoR.C. Combination of basal insulin and GLP-1 receptor agonist: Is this the end of basal insulin alone in the treatment of type 2 diabetes?Diabetol Metab Syndr20181012610.1186/s13098‑018‑0327‑429636825
     [Google Scholar]
  10. ØstergaardL. FrandsenC.S. DejgaardT.F. MadsbadS. Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes.Expert Rev Clin Pharmacol201710662163210.1080/17512433.2017.131310928349716
     [Google Scholar]
  11. VedtofteL. KnopF.K. VilsbøllT. Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide.Expert Rev Clin Pharmacol20158327328210.1586/17512433.2015.102945525816888
     [Google Scholar]
  12. AryaS. KajiA.H. BoermeesterM.A. PRISMA reporting guidelines for meta-analyses and systematic reviews.JAMA Surg2021156878979010.1001/jamasurg.2021.054633825806
     [Google Scholar]
  13. HigginsJ.P.T. ThomasJ. ChandlerJ. CumpstonM. LiT. PageM.J. WelchV.A. Cochrane handbook for systematic reviews of interventionsCochrane2024
     [Google Scholar]
  14. WangW. AgnerB.F.R. LuoB. LiuL. LiuM. PengY. QuS. StachlewskaK.A. WangG. YuanG. ZhangQ. NingG. DUAL I China: Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs.J Diabetes202214640141310.1111/1753‑0407.1328635762390
     [Google Scholar]
  15. PeiY. AgnerB.R. LuoB. DongX. LiD. LiuJ. LiuL. LiuM. LuY. NishidaT. XuX. MuY. DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin.Diabetes Obes Metab202123122687269610.1111/dom.1452234387411
     [Google Scholar]
  16. SestiG. BardtrumL. DagdelenS. HalladinN. HaluzíkM. ŐrsyP. RodríguezM. ArodaV.R. A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice.Diabetes Obes Metab202022587387810.1111/dom.1395731903724
     [Google Scholar]
  17. KakuK. ArakiE. TanizawaY. Ross AgnerB. NishidaT. RantheM. InagakiN. Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial.Diabetes Obes Metab201921122674268310.1111/dom.1385631407845
     [Google Scholar]
  18. WatadaH. KanekoS. KomatsuM. AgnerB.R. NishidaT. RantheM. NakamuraJ. Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double-blind, randomized trial.Diabetes Obes Metab201921122694270310.1111/dom.1385931423685
     [Google Scholar]
  19. Philis-TsimikasA. BillingsL.K. BuschR. PortilloC.M. SahayR. HalladinN. EggertS. BegtrupK. HarrisS. Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes.Diabetes Obes Metab20192161399140810.1111/dom.1366630761720
     [Google Scholar]
  20. BillingsL.K. DoshiA. GouetD. OviedoA. RodbardH.W. TentolourisN. GrønR. HalladinN. JodarE. Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: The DUAL VII randomized clinical trial.Diabetes Care20184151009101610.2337/dc17‑111429483185
     [Google Scholar]
  21. LinjawiS. BodeB.W. ChaykinL.B. CourrègesJ.P. HandelsmanY. LehmannL.M. MishraA. SimpsonR.W. The Efficacy of IDegLira (insulin degludec/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUAL III randomized clinical trial.Diabetes Ther20178110111410.1007/s13300‑016‑0218‑327943107
     [Google Scholar]
  22. RodbardH.W. BodeB.W. HarrisS.B. RoseL. LehmannL. JarlovH. ThurmanJ. Safety and efficacy of insulin degludec/liraglutide ( ID egLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial.Diabet Med201734218919610.1111/dme.1325627589252
     [Google Scholar]
  23. LingvayI. ManghiF.P. García-HernándezP. NorwoodP. LehmannL. Tarp-JohansenM.J. BuseJ.B. DUAL V Investigators. Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: The DUAL v randomized clinical trial.JAMA2016315989890710.1001/jama.2016.125226934259
     [Google Scholar]
  24. GoughS.C.L. BodeB. WooV. RodbardH.W. LinjawiS. PoulsenP. DamgaardL.H. BuseJ.B. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.Lancet Diabetes Endocrinol201421188589310.1016/S2213‑8587(14)70174‑325190523
     [Google Scholar]
  25. BuseJ.B. VilsbøllT. ThurmanJ. BlevinsT.C. LangbakkeI.H. BøttcherS.G. RodbardH.W. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).Diabetes Care201437112926293310.2337/dc14‑078525114296
     [Google Scholar]
  26. 6. glycemic targets: Standards of medical care in diabetes-2022.Diabetes Care202245S83S9610.2337/dc22‑S00634964868
     [Google Scholar]
  27. BlondeL. UmpierrezG.E. ReddyS.S. McGillJ.B. BergaS.L. BushM. ChandrasekaranS. DeFronzoR.A. EinhornD. GalindoR.J. GardnerT.W. GargR. GarveyW.T. HirschI.B. HurleyD.L. IzuoraK. KosiborodM. OlsonD. PatelS.B. Pop-BusuiR. SadhuA.R. SamsonS.L. StecC. TamborlaneW.V. TuttleK.R. TwiningC. VellaA. VellankiP. WeberS.L. American association of clinical endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update.Endocr Pract20222810923104910.1016/j.eprac.2022.08.00235963508
     [Google Scholar]
  28. BennettW.L. MaruthurN.M. SinghS. SegalJ.B. WilsonL.M. ChatterjeeR. MarinopoulosS.S. PuhanM.A. RanasingheP. BlockL. NicholsonW.K. HutflessS. BassE.B. BolenS. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations.Ann Intern Med2011154960261310.7326/0003‑4819‑154‑9‑201105030‑0033621403054
     [Google Scholar]
  29. NiswenderK.D. Basal insulin: Beyond glycemia.Postgrad Med20111234273710.3810/pgm.2011.07.230121680986
     [Google Scholar]
  30. BaggioL.L. DruckerD.J. Biology of Incretins: GLP-1 and GIP.Gastroenterology200713262131215710.1053/j.gastro.2007.03.05417498508
     [Google Scholar]
  31. FreemantleN. MamdaniM. VilsbøllT. KongsøJ.H. KvistK. BainS.C. IDegLira versus alternative intensification strategies in patients with type 2 diabetes inadequately controlled on basal insulin therapy.Diabetes Ther20156457359110.1007/s13300‑015‑0142‑y26582052
     [Google Scholar]
  32. HarrisK. NealyK.L. The Clinical use of a fixed-dose combination of insulin degludec and liraglutide (Xultophy 100/3.6) for the treatment of type 2 diabetes.Ann Pharmacother2018521697710.1177/106002801772634828799414
     [Google Scholar]
  33. HarrisS. AbrahamsonM.J. CerielloA. CharpentierG. EvansM. LehmannR. LieblA. LinjawiS. HoltR.I.G. HosszúfalusiN. RuttenG. VilsbøllT. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations.Drugs202080214716510.1007/s40265‑019‑01245‑331960258
     [Google Scholar]
  34. BlondeL. DippS. CadenaD. Combination glucose-lowering therapy plans in T2DM: case-based considerations.Adv Ther201835793996510.1007/s12325‑018‑0694‑029777519
     [Google Scholar]
  35. PerreaultL. RodbardH. ValentineV. JohnsonE. Optimizing fixed-Ratio combination therapy in type 2 diabetes.Adv Ther201936226527710.1007/s12325‑018‑0868‑930610613
     [Google Scholar]
  36. KanetoH. KoshidaR. BaxterM. Fixed-ratio combination of basal insulin and glucagon-like peptide-1 receptor agonists in the treatment of Japanese people with type 2 diabetes: An innovative solution to a complex therapeutic challenge.Diabetes Obes Metab202022S4243410.1111/dom.1409532436323
     [Google Scholar]
  37. Melzer-CohenC. ChodickG. NaftelbergS. ShehadehN. KarasikA. Metabolic control and adherence to therapy in type 2 diabetes mellitus patients using IDegLira in a real-world setting.Diabetes Ther202011118519610.1007/s13300‑019‑00725‑931808132
     [Google Scholar]
  38. DaviesM.J. GlahD. ChubbB. KonidarisG. McEwanP. Cost effectiveness of IDegLira vs. alternative basal insulin intensification therapies in patients with type 2 diabetes mellitus uncontrolled on basal insulin in a UK setting.PharmacoEconomics201634995396610.1007/s40273‑016‑0433‑927438706
     [Google Scholar]
  39. EricssonÅ. LundqvistA. Cost effectiveness of insulin degludec plus liraglutide (IDegLira) in a fixed combination for uncontrolled type 2 diabetes mellitus in Sweden.Appl Health Econ Health Policy201715223724810.1007/s40258‑016‑0301‑y28063135
     [Google Scholar]
  40. HuntB. MocarskiM. ValentineW.J. LangerJ. IDegLira versus insulin glargine U100: a long-term cost-effectiveness analysis in the US setting.Diabetes Ther20178353154410.1007/s13300‑017‑0251‑x28349444
     [Google Scholar]
  41. HuntB. GlahD. van der VlietM. Modeling the long-term cost-effectiveness of IDegLira in patients with type 2 diabetes who are failing to meet glycemic targets on basal insulin alone in the Netherlands.Diabetes Ther20178475376510.1007/s13300‑017‑0266‑328523483
     [Google Scholar]
  42. KvapilM. PráznýM. HolikP. RychnaK. HuntB. Cost-effectiveness of IDegLira versus insulin intensification regimens for the treatment of adults with type 2 diabetes in the Czech republic.Diabetes Ther2017861331134710.1007/s13300‑017‑0323‑y29063511
     [Google Scholar]
  43. RayaP.M. BlascoF.J.A. HuntB. MartinV. ThorstedB.L. BasseA. PriceH. Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence.Diabetes Obes Metab20192161349135610.1111/dom.1366030740861
     [Google Scholar]
/content/journals/cdr/10.2174/0115733998359708250822102217
Loading
Efficacy and Safety of IDegLira in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Curr. Diabetes Rev. 22, E15733998359708 (2026); https://doi.org/10.2174/0115733998359708250822102217
/content/journals/cdr/10.2174/0115733998359708250822102217
/content/journals/cdr/10.2174/0115733998359708250822102217
Loading

Data & Media loading...

Supplements

PRISMA checklist is available as supplementary material on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): A1c; CVD; IDegLira; Insulin Resistance (IR); obesity; type 2 diabetes mellitus

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test